Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ARWR Arrowhead Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: ARWR
Price (delayed)
$18.31
Market cap
$2.53B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.36
Enterprise value
$3.08B
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger
Highlights
The net income has surged by 77% since the previous quarter and by 69% year-on-year
ARWR's EPS has soared by 74% from the previous quarter and by 68% YoY
Arrowhead Pharmaceuticals's debt has surged by 85% YoY but it has decreased by 15% QoQ
The quick ratio has decreased by 38% YoY and by 16% from the previous quarter
Key stats
What are the main financial stats of ARWR
Market
Valuations
Earnings
Shares outstanding
138.1M
Market cap
$2.53B
Enterprise value
$3.08B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.38
Price to sales (P/S)
4.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.66
Revenue
$545.21M
Gross profit
$545.21M
Operating income
-$118.55M
Net income
-$143.97M
EBIT
-$78.54M
EBITDA
-$57.42M
Free cash flow
$9.6M
Per share
Balance sheet
Liquidity
EPS
-$1.36
EPS diluted
-$1.39
Free cash flow per share
$0.07
Book value per share
$5.42
Revenue per share
$4.09
TBVPS
$11.74
Total assets
$1.57B
Total liabilities
$889.27M
Debt
$740.51M
Equity
$683.32M
Working capital
$914.68M
Debt to equity
1.08
Current ratio
5.15
Quick ratio
4.99
Net debt/EBITDA
-9.66
Margins
Efficiency
Dividend
EBITDA margin
-10.5%
Gross margin
100%
Net margin
-26.4%
Operating margin
-21.7%
Return on assets
-12.5%
Return on equity
-46%
Return on invested capital
-4.8%
Return on capital employed
-5.8%
Return on sales
-14.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ARWR stock price
How has the Arrowhead Pharmaceuticals stock price performed over time
Intraday
-2.92%
1 week
9.05%
1 month
9.38%
1 year
-35.19%
YTD
-2.61%
QTD
15.89%
Financial performance
How have Arrowhead Pharmaceuticals's revenue and profit performed over time
Revenue
$545.21M
Gross profit
$545.21M
Operating income
-$118.55M
Net income
-$143.97M
Gross margin
100%
Net margin
-26.4%
The operating margin has surged by 100% since the previous quarter and by 98% year-on-year
Arrowhead Pharmaceuticals's net margin has surged by 100% QoQ and by 98% YoY
The operating income has surged by 81% since the previous quarter and by 75% year-on-year
The net income has surged by 77% since the previous quarter and by 69% year-on-year
Price vs fundamentals
How does ARWR's price correlate with its fundamentals
Growth
What is Arrowhead Pharmaceuticals's growth rate over time
Valuation
What is Arrowhead Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.38
P/S
4.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.66
ARWR's EPS has soared by 74% from the previous quarter and by 68% YoY
The price to book (P/B) is 81% lower than the last 4 quarters average of 17.4 and 75% lower than the 5-year quarterly average of 13.7
The equity has grown by 41% YoY
The price to sales (P/S) is 99% less than the last 4 quarters average of 439.9 and 96% less than the 5-year quarterly average of 125.1
Efficiency
How efficient is Arrowhead Pharmaceuticals business performance
ARWR's ROS has soared by 100% from the previous quarter and by 99% YoY
Arrowhead Pharmaceuticals's return on invested capital has surged by 90% YoY and by 88% QoQ
The company's return on equity has surged by 81% QoQ and by 69% YoY
The company's return on assets has surged by 80% QoQ and by 79% YoY
Dividends
What is ARWR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ARWR.
Financial health
How did Arrowhead Pharmaceuticals financials performed over time
ARWR's total assets is 77% higher than its total liabilities
The total liabilities has surged by 93% year-on-year but it has declined by 7% since the previous quarter
ARWR's total assets has soared by 65% YoY and by 55% QoQ
Arrowhead Pharmaceuticals's debt is 8% higher than its equity
The debt to equity has plunged by 93% from the previous quarter but it has grown by 30% YoY
Arrowhead Pharmaceuticals's debt has surged by 85% YoY but it has decreased by 15% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.